Pegargiminase

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pegargiminase
Accession Number
DB06592
Description

Pegargiminase is an anticancer agent.

Type
Small Molecule
Groups
Investigational
Synonyms
  • ADI-PEG 20
  • Arginine deiminase pegylated
  • Pegargiminase
  • Pegylated arginine deiminase

Pharmacology

Indication

Investigated for use/treatment in melanoma and hepatocellular carcinoma.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
0B7PYQ9YRT
CAS number
1394129-74-8

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentHepatocellular Carcinoma1
2CompletedTreatmentAcute Myeloid Leukemia (AML)1
2CompletedTreatmentHepatocellular Carcinoma1
2CompletedTreatmentMalignant Melanoma of Skin / Melanoma (Skin)1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentUnresectable Hepatocellular Carcinoma1
2RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2TerminatedTreatmentSmall Cell Lung Cancer (SCLC)1
2Unknown StatusTreatmentMalignant Pleural Mesothelioma (MPM)1
2, 3RecruitingTreatmentMesothelioma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on March 19, 2008 10:39 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates